Keyphrases
Angiotensin-converting Enzyme Inhibitor (ACEi)
100%
Human Skin
100%
Essential Hypertension
100%
Skin Blood Flow
100%
Peripheral Vascular
30%
Vascular Effects
30%
Hypertension
30%
Specific Intent
20%
Signaling Mechanism
20%
Cutaneous Microcirculation
20%
Hypertensive
20%
Clinical Outcomes
20%
Intervention Strategies
10%
Therapeutic Target
10%
Vasculature
10%
Sectional Approach
10%
Proposed Work
10%
Microvascular Function
10%
Pharmacotherapy
10%
Induced Damage
10%
Associated Diseases
10%
Therapeutic Benefits
10%
Gasotransmitter
10%
Secondary Treatment
10%
Nave
10%
Specific Mechanisms
10%
Microvascular Dysfunction
10%
Lipophilic
10%
Randomized Double-blind
10%
Sulfhydryl Group
10%
Highly Effective
10%
Clinical Treatment
10%
Vascular Dysfunction
10%
Signal Transduction Inhibitors
10%
Redox
10%
Joint National Committee
10%
Inhibitor Therapy
10%
Sulfhydryl
10%
Cardiovascular Disease
10%
Reduced Mortality
10%
Vasodilation
10%
Non-vascular
10%
Inhibitor-2
10%
Thiazide Diuretics
10%
Hydrogen Sulfide
10%
Endothelium
10%
Therapeutic Control
10%
Blood Vasculature
10%
Medicine and Dentistry
ACE Inhibitor
100%
Skin Blood Flow
100%
Essential Hypertension
100%
Signaling Mechanism
20%
Microcirculation
20%
Drug Therapy
20%
Vascularity
20%
Antihypertensive Agent
10%
Thiazide Diuretic Agent
10%
Thiol Group
10%
Thiol Derivative
10%
Gasotransmitter
10%
In Vitro
10%
Disease
10%
Vasodilatation
10%
Cardiovascular Disease
10%
Diuretic Agent
10%
Hydrogen Sulfide
10%
Pharmacology, Toxicology and Pharmaceutical Science
Dipeptidyl Carboxypeptidase Inhibitor
100%
Pharmacotherapy
20%
Disease
10%
Thiazide Diuretic Agent
10%
Diuretic Agent
10%
Antihypertensive Agent
10%
Hydrogen Sulfide
10%
Thiol Group
10%